• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

管理艾滋病毒感染者的兴奋剂使用:从行为到药物的减少伤害策略。

Managing Stimulant Use Among People With HIV: Harm-Reduction Strategies From Behavior to Medication.

作者信息

Blair Cheríe S, Shoptaw Steven J

机构信息

University of California Los Angeles, Los Angeles, California, USA.

出版信息

Top Antivir Med. 2024 Dec 23;32(5):571-578.

PMID:39765236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11737809/
Abstract

Stimulant use disorder poses substantial challenges to the health and well-being of people with HIV, contributing to increased HIV transmission risk and poor clinical outcomes. This article highlights the cultural significance of stimulant use, its epidemiology, and the latest evidencebased interventions for stimulant use disorder among individuals with HIV. Contingency management has emerged as the most effective treatment, with harm-reduction approaches serving as vital tools for improving the health of individuals unable or unwilling to achieve abstinence. Integrated care models that combine behavioral interventions, pharmacotherapy, and harm reduction offer a promising framework to improve health outcomes for people with HIV who use stimulants, addressing the intersection of stimulant use and HIV in care settings.

摘要

兴奋剂使用障碍给艾滋病毒感染者的健康和福祉带来了重大挑战,增加了艾滋病毒传播风险,并导致不良临床结果。本文强调了兴奋剂使用的文化意义、其流行病学以及针对艾滋病毒感染者中兴奋剂使用障碍的最新循证干预措施。应急管理已成为最有效的治疗方法,减少伤害的方法是改善无法或不愿戒除兴奋剂者健康的重要工具。将行为干预、药物治疗和减少伤害相结合的综合护理模式,为改善使用兴奋剂的艾滋病毒感染者的健康结果提供了一个有前景的框架,在护理环境中解决了兴奋剂使用与艾滋病毒的交叉问题。

相似文献

1
Managing Stimulant Use Among People With HIV: Harm-Reduction Strategies From Behavior to Medication.管理艾滋病毒感染者的兴奋剂使用:从行为到药物的减少伤害策略。
Top Antivir Med. 2024 Dec 23;32(5):571-578.
2
Psychosocial interventions for stimulant use disorder.兴奋剂使用障碍的心理社会干预。
Cochrane Database Syst Rev. 2024 Feb 15;2(2):CD011866. doi: 10.1002/14651858.CD011866.pub3.
3
Patient and Staff Perspectives on the Impacts and Challenges of Hospital-Based Harm Reduction.患者和员工对基于医院的减少伤害的影响和挑战的看法。
JAMA Netw Open. 2024 Feb 5;7(2):e240229. doi: 10.1001/jamanetworkopen.2024.0229.
4
Trends in stimulant use among patients with opioid use disorder receiving substance use treatment: Findings from a prospective cohort study from 2013 to 2020.接受物质使用治疗的阿片类物质使用障碍患者中兴奋剂使用的趋势:一项2013年至2020年前瞻性队列研究的结果
Drug Alcohol Depend. 2025 Aug 1;273:112703. doi: 10.1016/j.drugalcdep.2025.112703. Epub 2025 May 16.
5
Interventions for tobacco use cessation in people living with HIV.HIV 感染者的戒烟干预措施。
Cochrane Database Syst Rev. 2024 Aug 5;8(8):CD011120. doi: 10.1002/14651858.CD011120.pub3.
6
Association Between Stimulant Treatment and Substance Use Through Adolescence Into Early Adulthood.兴奋剂治疗与物质使用的关联:从青少年到成年早期。
JAMA Psychiatry. 2023 Sep 1;80(9):933-941. doi: 10.1001/jamapsychiatry.2023.2157.
7
Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders.针对正在接受物质使用障碍治疗或已康复的人群的戒烟干预措施。
Cochrane Database Syst Rev. 2016 Nov 23;11(11):CD010274. doi: 10.1002/14651858.CD010274.pub2.
8
Pharmacotherapy for anxiety and comorbid alcohol use disorders.焦虑症合并酒精使用障碍的药物治疗
Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2.
9
Interventions to reduce harm from continued tobacco use.减少持续吸烟危害的干预措施。
Cochrane Database Syst Rev. 2016 Oct 13;10(10):CD005231. doi: 10.1002/14651858.CD005231.pub3.
10
Development and Pilot Testing of an Addiction Clinic-Based Pre-Exposure Prophylaxis Uptake and Adherence Intervention for Women with Substance Use Disorders: Protocol for a Pilot Randomized Trial.基于成瘾门诊的物质使用障碍女性暴露前预防接受与依从性干预的开发与试点测试:一项试点随机试验方案
JMIR Res Protoc. 2025 May 23;14:e64961. doi: 10.2196/64961.

引用本文的文献

1
High Rates of Drug Use and Chemsex Among PrEP Users and People with HIV in Milan Highlight Need for Targeted Interventions.米兰的暴露前预防(PrEP)使用者和艾滋病毒感染者中药物使用率和化学性行为发生率高,凸显了针对性干预措施的必要性。
AIDS Behav. 2025 Jun 9. doi: 10.1007/s10461-025-04778-9.

本文引用的文献

1
Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.在ADAPT-2试验中对纳曲酮联合安非他酮减少甲基苯丙胺使用情况的长期观察。
Addiction. 2024 Oct;119(10):1840-1845. doi: 10.1111/add.16529. Epub 2024 Jun 10.
2
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.美国酒精滥用与药物依赖协会/美国成瘾医师协会临床实践指南:兴奋剂使用障碍管理
J Addict Med. 2024;18(1S Suppl 1):1-56. doi: 10.1097/ADM.0000000000001299.
3
Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder.在一项随机临床试验中,比较使用缓释纳曲酮和安非他酮治疗男性甲基苯丙胺使用障碍的性取向差异。
Drug Alcohol Depend. 2023 Sep 1;250:110899. doi: 10.1016/j.drugalcdep.2023.110899. Epub 2023 Jul 17.
4
Racial, gender, and psychosocial disparities in viral suppression trends among people receiving coordinated HIV care in Los Angeles County.在洛杉矶县接受协调艾滋病毒护理的人群中,病毒抑制趋势存在种族、性别和社会心理差异。
AIDS. 2023 Jul 15;37(9):1441-1449. doi: 10.1097/QAD.0000000000003578. Epub 2023 Apr 13.
5
Contingency Management for Integrated Harm Reduction Among Men Who Have Sex with Men Who Use Methamphetamine in Los Angeles: A Pilot Assessment.在洛杉矶,针对同时使用美沙酮的男男性行为者进行综合减少伤害的应急管理:一项试点评估。
AIDS Behav. 2023 Jun;27(6):1962-1971. doi: 10.1007/s10461-022-03929-6. Epub 2022 Nov 21.
6
A Chronic Condition Disguised as an Acute Event: the Case for Re-thinking Stimulant Overdose Death.伪装成急性事件的慢性疾病:重新思考兴奋剂过量死亡的案例。
J Gen Intern Med. 2022 Oct;37(13):3462-3464. doi: 10.1007/s11606-022-07692-1. Epub 2022 Jun 17.
7
Frequency of reported methamphetamine use linked to prevalence of clinical conditions, sexual risk behaviors, and social adversity in diverse men who have sex with men in Los Angeles.在洛杉矶的不同男男性行为者中,报告的甲基苯丙胺使用频率与临床状况、性风险行为和社会逆境的流行程度相关。
Drug Alcohol Depend. 2022 Mar 1;232:109320. doi: 10.1016/j.drugalcdep.2022.109320. Epub 2022 Jan 19.
8
Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis.米氮平治疗苯丙胺和甲基苯丙胺使用障碍:系统评价和荟萃分析。
Drug Alcohol Depend. 2022 Mar 1;232:109295. doi: 10.1016/j.drugalcdep.2022.109295. Epub 2022 Jan 11.
9
Digital delivery of a contingency management intervention for substance use disorder: A feasibility study with DynamiCare Health.数字化传递物质使用障碍的应急管理干预:与 DynamiCare Health 的可行性研究。
J Subst Abuse Treat. 2021 Jul;126:108425. doi: 10.1016/j.jsat.2021.108425. Epub 2021 Apr 21.
10
Bupropion and Naltrexone in Methamphetamine Use Disorder.丁丙诺啡与安非他酮治疗甲基苯丙胺使用障碍
N Engl J Med. 2021 Jan 14;384(2):140-153. doi: 10.1056/NEJMoa2020214.